Artificical Intelligence (AI) in Drug Discovery ACF Equity Research 23092022
Drug discovery and development requires colossal upfront investment. The process typically takes over a decade. A large number of product candidates fail to prove efficacy or safety during preclinical and clinical research phases or fail to pass regulatory scrutiny. According to Deloitte, the average cost of drug discovery and development increased over 80% between 2010 and 2018 from $1.188bn to $2.168bn, CAGR 7.8%, per successfully launched drug.
BioXcel Therapeutics is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify therapies in neuroscience and immuno-oncology. The company's drug approach utilize existing approved drugs and/or clinically validated product candidates together data and proprietary machine learning algorithms to identify new therapeutic indices. The company's clinical development programs are BXCL501, which is designed for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, which is designed for treatment of a rare form of prostate cancer, pancreatic cancer and cancers in combination with other immuno-oncology agents.
E-Therapeutics is a drug discovery company with a proprietary in silico discovery platform based on the application of network science to the modelling and analysis of cellular processes and utilizing public and proprietary chemical biology and multi-omics data. The therapeutic focus of Co.'s discovery activity is in areas of disease with unmet medical need, including immuno-oncology.
ACF Equity Research is an independent research house specialising in the highest specification independent equity research for corporate clients.
We deliver premium independent corporate sponsored equity research characterised by its accuracy, clarity and foresight based upon a fundamental valuation approach.
Our independent research is designed to educate our professional investor readers with an emphasis on clear and accurate explanations. Our mission is to improve company’s liquidity through credible equity research services, excellent international distribution and reliable access for investment managers.
We believe in the importance and value of clarity, the careful articulation of technical ideas, concepts and solutions.
Our team of analysts are independently minded individuals who believe in thoroughness, technical competence and clear punchy communications.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.